Biohaven Pharmaceutical and its wholly-owned Asia-Pacific subsidiary company, BioShin, announced the National Medical Products Administration, or NMPA, formerly, the China FDA, has accepted the investigational new drug, or IND, application for rimegepant, Biohaven’s lead oral calcitonin gene-related peptide, or CGRP, receptor antagonist product candidate, for the treatment of migraine. CGRP receptor antagonists represent a novel class of drug candidates for the treatment of migraine and are the first new class for the treatment of migraine in over 25 years. CGRP receptor antagonists potentially offer an alternative to current agents, particularly for patients who have contraindications to the use of triptans, such as those with underlying cardiovascular diseases, or those who have an inadequate response to standard therapies.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.